MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from maturitiesof investments$149,500K Net cash provided by(used in) investing...$66,100K Canceled cashflow$83,400K Net increase incash, cash...$1,686K Canceled cashflow$64,414K Purchases of investments$81,731K Purchases of property andequipment$1,669K Stock-based compensationexpense$14,720K Accounts payable$1,536K Depreciation expense$1,356K Non-cash operating leaseexpense$1,027K Prepaid expenses andother current assets-$190K Other assets-$137K Proceeds from exercise ofstock options$1K Net cash used inoperating activities-$63,665K Net cash (used in)provided by financing...-$749K Canceled cashflow$18,966K Canceled cashflow$1K Net loss-$77,905K Payments of taxwithholdings related to...$750K Accrued expenses andother liabilities-$3,353K Operating leaseliabilities-$936K Net amortization ofpremiums and accretion of...$437K
Cash Flow
source: myfinsight.com

Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics, Inc. (ACRV)